Laszlo G Radvanyi

Laszlo G Radvanyi

UNVERIFIED PROFILE

Are you Laszlo G Radvanyi?   Register this Author

Register author
Laszlo G Radvanyi

Laszlo G Radvanyi

Publications by authors named "Laszlo G Radvanyi"

Are you Laszlo G Radvanyi?   Register this Author

38Publications

1254Reads

45Profile Views

Targeting the cancer mutanome of breast cancer.

Nat Med 2018 06;24(6):703-704

Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-018-0065-zDOI Listing
June 2018

Tumor-Infiltrating Lymphocyte Therapy: Addressing Prevailing Questions.

Cancer J 2015 Nov-Dec;21(6):450-64

From the Department of Immunology, H. Lee Moffitt Cancer Center; and Lion Biotechnologies, Tampa, FL.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/journalppo/2015/11000/Tumor_Inf
Web Search
http://dx.doi.org/10.1097/PPO.0000000000000162DOI Listing
September 2016

Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2.

Oncotarget 2016 Jun;7(24):36074-36091

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.8683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094984PMC
June 2016

Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma.

J Immunother 2014 Nov-Dec;37(9):448-60

*Department of Melanoma Medical Oncology †Division of Pediatrics, MD Anderson Cancer Center, Houston, TX ‡Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center and trans-NIH Center for Human Immunology, National Institutes of Health, Bethesda, MD ∥Lion Biotechnologies, Woodland Hills, CA §Sidra Medical and Research Hospital, Doha, Qatar.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199393PMC
November 2015

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties.

Oncoimmunology 2015 Aug 16;4(8):e1014246. Epub 2015 Mar 16.

Department of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center ; Houston, TX USA ; Lion Biotechnologies ; Tampa, FL USA ; Department of Immunology; H Lee Moffitt Cancer Center ; Tampa, FL USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1014246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570103PMC
August 2015

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.

Cancer Immunol Res 2015 Jun 20;3(6):602-9. Epub 2015 Mar 20.

Department of Melanoma Medical Oncology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Immunology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457616PMC
June 2015

Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.

BioDrugs 2015 Feb;29(1):15-30

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s40259-014-0114
Web Search
http://link.springer.com/10.1007/s40259-014-0114-1
Publisher Site
http://dx.doi.org/10.1007/s40259-014-0114-1DOI Listing
February 2015

Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy.

Oncoimmunology 2013 Sep 3;2(9):e25581. Epub 2013 Jul 3.

Department of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA ; The Immunology Program of the University of Texas Health Science Center, Graduate School of Biomedical Sciences; The University of Texas MD Anderson Cancer Center; Houston, TX USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.25581DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850170PMC
September 2013

Advances in the development of cancer immunotherapies.

Trends Immunol 2013 Feb 30;34(2):90-8. Epub 2012 Sep 30.

Center for Cancer Immunology Research, GU and Melanoma Medical Oncology Department, MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2012.08.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565019PMC
February 2013

New insights on the role of CD8(+)CD57(+) T-cells in cancer.

Oncoimmunology 2012 Sep;1(6):954-956

Department of Melanoma Medical Oncology; University of Texas M.D. Anderson Cancer Center; Houston, TX USA ; University of Texas Graduate School of Biomedical Sciences; Houston, TX USA ; University of Texas Medical School at Houston; Houston, TX USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.20307DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489757PMC
September 2012

BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.

Clin Cancer Res 2012 Apr 21;18(8):2326-35. Epub 2012 Feb 21.

Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2515DOI Listing
April 2012

Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Semin Oncol 2012 Apr;39(2):215-26

Department of Melanoma Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2012.01.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500663PMC
April 2012

2E8 binds to the high affinity I-domain in a metal ion-dependent manner: a second generation monoclonal antibody selectively targeting activated LFA-1.

J Biol Chem 2010 Oct 19;285(43):32860-8. Epub 2010 Aug 19.

Section of Transplantation Immunology, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center,Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M110.111591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2963386PMC
October 2010

Development and application of 'phosphoflow' as a tool for immunomonitoring.

Expert Rev Vaccines 2010 Jun;9(6):631-43

Department of Melanoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/erv.10.59DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933839PMC
June 2010

A new approach for the large-scale generation of mature dendritic cells from adherent PBMC using roller bottle technology.

J Immune Based Ther Vaccines 2008 Mar 6;6. Epub 2008 Mar 6.

Department of Melanoma Medical Oncology, University of Texas, M,D, Anderson Cancer Center, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-6-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292722PMC
March 2008

Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.

Clin Cancer Res 2006 Aug;12(16):4794-803

Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0944DOI Listing
August 2006

Immunosuppression in melanoma immunotherapy: potential opportunities for intervention.

Clin Cancer Res 2006 Apr;12(7 Pt 2):2359s-2365s

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-2537DOI Listing
April 2006